WANY
KYMR icon

Wealthspire Advisors (New York)’s Kymera Therapeutics KYMR Stock Holding History

Wealthspire Advisors (New York)’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5
Closed -$283 – 2041
2025
Q3 		$283 Buy
+5
New +$226 ﹤0.01% 2904

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Wealthspire Advisors (New York)'s KYMR Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Kymera Therapeutics (KYMR) in Q4 2025, closing a stake of 5 shares — an estimated $283 sold.

Wealthspire Advisors (New York) first reported a position in KYMR in Q3 2025 and held it in 1 quarter. The position peaked at $283 in Q3 2025. 254 funds tracked by Wall St. Rank hold KYMR as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Kymera Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 5 Kymera Therapeutics shares in Q4 2025, an estimated $283.
  • Wealthspire Advisors (New York) first reported a position in Kymera Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Kymera Therapeutics position peaked at $283 in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.